Cellectis SA, a pioneering gene-editing company focused on developing immunotherapies,opened for trading on The Nasdaq Stock Market on March 25, 2015.
Cellectis SA, a pioneering gene-editing company focused on developing immunotherapies,opened for trading on The Nasdaq Stock Market on March 25, 2015.